Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 1

Conditions

Fallopian Tube Neoplasms 8Ovarian Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 5Prostatic Neoplasms 4Triple Negative Breast Neoplasms 3Glioma 3Endometrial Neoplasms 3Wilms Tumor 2Small Cell Lung Carcinoma 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Ependymoma 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Biopsy 6trametinib 2olaparib 2dehydroftorafur 2cobimetinib 2atezolizumab 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Capecitabine 2varlilumab 1tremelimumab 1tofacitinib 1tivozanib 1pevonedistat 1peposertib 1pembrolizumab 1nilotinib 1fludarabine 1durvalumab 1ceralasertib 1binimetinib 1avelumab 1aldesleukin 1Taxes 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Cholangiocarcinoma × olaparib × Clear all
NCT03878095 2026-06-01

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
24 enrolled 12 charts
Gastrointestinal

Cholangiocarcinoma

NCT03212274 2026-02-19

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
89 enrolled
CNSGastrointestinal

Glioblastoma, Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡